LaNova Medicines and CTTQ Announces the IND Approval of Combination Therapies by NMPA
-
2024-10-09
-
Share:
SHANGHAI, October 9th, 2024 – LaNova Medicines Ltd. announced that the investigational new drug (IND) for LM-108 in combination with CTTQ's benmelstobart injection/penpulimab, has been approved by China NMPA.
LM-108 is the targeted monoclonal antibody independently developed by LaNova Medicines; benmelstobart injection is an innovative humanized anti-PD-L1 monoclonal antibody; and penpulimab is a novel differentiated anti-PD-1 monoclonal antibody.